Schall Law Firm Invites MLTX Investors to Join Class Action Lawsuit Against MoonLake Immunotherapeutics

The Schall Law Firm, a prominent entity specializing in shareholder rights, recently announced an ongoing class action lawsuit against MoonLake Immunotherapeutics, traded under NASDAQ as MLTX. This legal action stems from allegations that the company violated key sections of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), as well as Rule 10b-5 set forth by the U.S. Securities and Exchange Commission.

For investors who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, there is a pressing opportunity to take action before the deadline of December 15, 2025. This move is crucial for those who may have suffered financial damages due to the alleged misleading statements made by the company regarding its drug candidate, sonelokimab (SLK).

Allegations Against MoonLake Immunotherapeutics

According to the complaint filed, MoonLake purportedly provided false and misleading information to its investors, specifically regarding the efficacy of its monoclonal antibody product, sonelokimab. The company had been promoting SLK as superior to other available treatments, a claim that was determined to be unfounded based on trial results. An important highlight was the Phase 3 trial results that were described by analysts as